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Introduction
Only 2–15% of transcriptionally active genes are regulated by 
the histone acetylation state of their promoter and many of these 
genes are active in cell cycle control and apoptosis.1 Modulating 
the cellular histone acetylation/deacetylation state using specific 
inhibitors to histone deacetylases represents a potential approach 
for cancer therapy. Inhibitors of histone deacetylases (HDACi) 
are anticancer agents with the potential to alter gene expression 
and induce cell death, differentiation and/or cell cycle arrest in 
tumor cells by inducing histone hyperacetylation. In vitro and in 
vivo studies have shown that HDACi, while relatively non-toxic 
to normal cells, have selective toxicity against tumor cell lines.2 
Many of these compounds are derivatives of hydroxamic acid and 
inhibit HDAC activity by blocking the catalytic site.
Almost all HDACi can induce cell cycle arrest, differen-
tiation or apoptosis in vitro, and many have potent anti-tumor 
activities in vivo, e.g., TSA, MS-27-275, Romidepsin, PXD101, 
PCI-24781, ITF2357, MGCD0103, MS-275, SAHA, valproic 
acid and LBH589.3-6 Additionally, many HDACi are active in 
the absence of wild type p53 expression.7 Several HDACi are in 
Phase I and II clinical trials and some are in Phase III trials or 
already in therapeutic use for hematological malignancies (e.g., 
SAHA8 and Romidepsin9). An important advantage of HDACi 
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is their hydrophobic structure that allows them to pass the blood-
brain barrier suggesting they may be valuable therapeutics for 
CNS malignancies.
Despite the increasingly wide-spread use of HDACi in clini-
cal trials there is little literature available describing the meth-
ods by which histone acetylation analysis may be monitored and 
measured during the course of a patient’s treatment, how samples 
should be treated and stored to retain optimal measurement of 
histone acetylation, nor any detailed information on typical lev-
els of histone acetylation in untreated peripheral blood. Although 
the therapeutic actions of HDACi are directed at tumors, these 
are not always available for direct or continuous assessment, 
whereas blood is more easily accessible to monitor a patient’s dose 
response to an HDACi. Furthermore, methods of analysis in 
peripheral blood are also likely to be applicable to liquid tumors 
including the leukemias, myelodysplastic syndromes and dis-
seminated solid tumors.
We have used cord or peripheral blood as a source of human 
leukocytes, and have performed a comparative analysis of blood 
sample processing methods and their impact on histone acetyla-
tion as well as developing a flow cytometric method for the analy-
sis of histone acetylation in isolated leukocytes. We have extended 
our analyses on the in vitro effects of LBH589 on histone acety-
lation and describe data for histone acetylation in blood from 
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up to nine weeks and then lysed for western blotting. This experi-
ment was designed to both mimic the conditions a clinical blood 
sample might be exposed to in a patient treated with an HDACi, 
and to examine the effect of blood processing and storage on the 
retention of histone acetylation in leukocytes. All stored leuko-
cyte cell pellets were lysed in protein lysis buffer and examined 
by western blotting (Fig. 1A and B). Acetylated histone H3 was 
detected as a band at approximately 16 KDa and acetylated his-
tone H4 at 12 KDa. The loading control was β-actin, migrat-
ing at 42 KDa. The leukemia cell line 697 treated with 100 nM 
LBH589 served as a positive control. For quantitative analysis of 
histone acetylation, western blot membranes were scanned and 
adjusted for concentration variations by normalization to the ref-
erence protein β-actin. The DMSO data were subtracted from 
the data generated from LBH589 treatments. The positive con-
trol sample from the 697 leukemia cell line was assigned a value 
of 1.0 and all other data adjusted relative to this value. The results 
are shown in Figure 2.
These data show, first, that while the levels of histone H3 and 
H4 acetylation in normal untreated blood are low, histone H4 
acetylation levels are consistently higher than histone H3 acety-
lation and that post LBH589 treatment significant increases in 
both histone H3 and H4 acetylation are detectable by western 
blotting. Second, there are few differences in histone H3 and H4 
acetylation between blood processed by either red cell lysis or 
Ficoll-Paque. This suggests that mononuclear cells (Ficoll-Paque 
PLUS) and leukocytes (red cell lysis) have similar levels of nuclear 
histone acetylation. Third, after storage of leukocyte and mono-
nuclear cell pellets for eight weeks at -80°C, histone acetylation 
is still detectable. However, histone acetylation is reduced by the 
re-introduction of leukocytes into cord blood, independently of 
the processing method. This reduction in histone acetylation is 
unlikely to be due to loss of cell viability, as the cells re-intro-
duced to blood prior to processing were stored with their paired 
unprocessed control sample for an equivalent period of time and 
under identical conditions. The differences may be due to the 
lability of histone acetylation in the blood milieu. In support of 
this, preliminary studies suggested that increased histone acety-
lation was not detectable in isolated leukocytes after the direct 
application of 100 nM LBH589 in vitro to cord or peripheral 
blood. This does not appear to be due to a loss of cell viability 
because preliminary studies on whole blood show that the major-
ity of both cord and peripheral blood cells retain viability for 
at least 72 h (Fig. 3). It may be due to the fact that leukocytes, 
outside the body, in conditions under which they are no longer 
actively metabolizing, are unable to continue to acetylate histone 
and that in certain conditions histones may become deacetylated.
Qualitative analysis of histone acetylation in leukocytes. 
Mononuclear cells were separated from cord blood by Ficoll-
Paque, incubated for 24 h with 100 nM LBH589 or 0.1% DMSO 
in RPMI, cyto-spun onto slides and acetylation detected using 
anti-acetylated histone H3 or anti-acetylated histone H4 anti-
bodies. The cells were viewed using confocal microscopy and 
digitized images are shown in Figure 4. Histone acetylation was 
readily detectable by this method; however, differences in the 
localization of acetylated histone H3 and histone H4 were noted. 
four patients treated with a single infusion of LBH589 as part of 
an ongoing Phase I clinical trial examining the safety, pharma-
cokinetics and effectiveness of LBH589 against refractory solid 
tumors of childhood. This study will be of interest to clinicians 
and scientists monitoring the effects of HDACi in blood in clini-
cal trials or in related research studies.
Results
Effect of sample processing on leukocyte acetylation and detec-
tion of histone acetylation by western blotting. In order to 
determine whether histone acetylation could be lost from leu-
kocytes during processing, 2 × 107 leukocytes, separated from 
their original blood source by either red cell lysis or Ficoll-Paque, 
were incubated with 100 nM LBH589 in RPMI for 24 h at 37°C 
in vitro to promote histone acetylation. Equivalent incubations 
were set up as controls in 0.1% DMSO in RPMI. Cells from each 
incubation, were counted and divided into equal parts compris-
ing 1 × 107 cells. One cell aliquot comprising 1 × 107 cells was 
placed back into separated cord blood depleted of leukocytes by 
centrifugation, and processed immediately either by Ficoll-Paque 
or red cell lysis, and the cells collected. The paired control cells, 
comprising 1 × 107 cells, were collected by centrifugation and 
stored at the same time. All cell pellets were stored at -80°C for 
Figure 1. Western blot showing histone h3 and h4 acetylation in leu-
kocytes separated by (A) Ficoll-paque pLUs, or (B) red cell lysis. Twenty 
micrograms of protein was loaded in each lane of 15% sDs-pAGE gels. 
Rabbit anti-acetyl histone h3 detected a protein band at approximately 
16 KDa and rabbit anti-acetyl histone h4 detected a band at 12 KDa; 
mouse anti-β actin (the loading control) recognized a protein band at 
42 KDa. The secondary antibody anti-mouse cy3 has red fluorescence 
and the anti-rabbit cy5 has green fluorescence. Lane 1, size marker. 
Lane 2, pre-treatment leukocytes separated by Ficoll-paque or red 
cell lysis. Lane 3, 0.1% DMsO treated for 24 h. Lane 4, 100 nM LBh589 
treated for 24 h. Lane 5, DMsO treated post-separation from leuko-
cyte-depleted blood. Lane 6, LBh589 treated post-separation from 
leukocyte-depleted blood. Lane 7; control 697 cells incubated with  
100 nM LBh589 for 24 h.
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with time, histone H3 and H4 acetylation was lost in fixed cells 
after prolonged storage at 4°C. Samples fixed and stored at 4°C 
for nine weeks were shown to have lost 25–50% of their base-line 
histone acetylation (data not shown).
In summary, flow cytometry is a good method for the quan-
titative detection of histone acetylation, and cells may be stored 
un-fixed at 4°C and 20°C for up to 72 h without a marked loss 
of histone acetylation. However, it is recommended that even if 
Histone H3 acetylation was more localized to the periphery of 
the nucleus and was quite diffuse within the body of the nucleus, 
whereas acetylated histone H4 was more concentrated within the 
nucleus. The qualitative differences in histone H3 and histone 
H4 acetylation detected by western blotting were also confirmed 
using this method.
Detection of histone acetylation by flow cytometry and 
effect of cell storage on histone acetylation. A flow cytometry 
method, extending that described in Ronzoni et al. was devel-
oped to monitor histone acetylation. Blood leukocytes in culture 
were treated with 100 nM LBH589 for 24 h and histone acetyla-
tion was then examined over a total period of 96 h to monitor 
any changes in histone acetylation occurring during the storage 
of un-fixed cells at 4°C. The procedure was repeated and cells 
stored at 20°C and 37°C to determine the effect of different tem-
perature storage conditions on histone acetylation. Leukocytes 
were separated from 5 mL buffy coat blood by red cell lysis, and 
a sample of 8 × 105 cells was fixed in 1% paraformaldehyde and 
stored at 4°C (pre-treatment sample). The remaining leuko-
cytes were incubated in RPMI/10% FBS at a concentration of 
107 cells/mL with either 100 nM LBH589, or 0.1% DMSO, for 
24 h. After the 24 h treatment, the cells were washed in 
RPMI/10% FBS and aliquots of 8 × 105 cells were fixed in 1% 
paraformaldehyde for analysis (0 h storage time point). The 
remaining cells were stored unfixed at 4°C, and at 20°C and 
37°C in RPMI/10% FBS for up to 96 h. Aliquots of the cells 
kept at 4°C, 20°C or 37°C were then fixed for analysis at 24, 
48, 72 and 96 h time points. The fixed cells were exposed to 
anti-acetylated histone antibodies, followed by incubation with 
the secondary antibody, donkey anti-rabbit IgG (H + L) Alexa 
Fluor 488. Data were collected using the BD FACSDiva software 
and analyzed using the software package FCS Express Research 
Edition. DMSO diluent data at each time point was histogram 
subtracted from 100 nM LBH589 data of peripheral blood leu-
kocytes using the analysis program FCS Express. The results are 
presented in Figure 5.
Both histone H3 and histone H4 acetylation were detected 
by this method and showed the same relative differences that 
were detected by both western blotting and immunohistochem-
istry after 24 h incubation with LBH589. Histone H3 and H4 
acetylation was detectable over the entire 96 h incubation period 
at all temperatures. Increasing histone H3 and H4 acetylation 
was particularly noted during the 4°C and 20°C incubations (H3 
only); however, this was not as evident at 37°C. After 96 h at 
37°C, a significant drop in both histone H3 and H4 acetylation 
was observed. Both the mean and median values are shown in 
Figure 5 because, although the mean is the average value of the 
fluorescence intensity produced by the analysis, the distribution 
of flow cytometry data are often skewed and in these instances 
the median fluorescence is a better measure. These results suggest 
that at 4°C and 20°C histone acetylation may increase to levels 
greater than those initially encountered immediately following 
treatment, in particular for histone H3 acetylation.
Treated and control leukocytes were analyzed by flow cytom-
etry at the same time, and all samples were stored post-fixation 
for up to one week prior to analysis. However, it was noted that 
Figure 3. percentage of live leukocytes in cord (squares) and periph-
eral blood (triangles) serially isolated over 4 d. Error bars represent the 
standard error from triplicate analyses.
Figure 2. Quantitative analysis of acetylation from western blotting. 
Bands representing acetylated histone were adjusted for β-actin inten-
sity and normalized to those of the positive control, LBh589-treated 
697 leukemia cells. Data are shown for anti-acetylated histone h3 and 
h4 on cells extracted by (A) Ficoll-paque pLUs and (B) red cell lysis. Day 
0 indicates the pre-treatment sample. Lanes labeled as 1st extraction 
represent post-incubation leukocytes treated with 100 nM LBh589 for 
24 h and 2nd extraction represent leukocytes treated with LBh589 for 
24 h and then re-separated from leukocyte depleted blood.
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a decrease to 24 h followed by an increase 
to 48 h. Because histone acetylation was 
not examined after 6 h it is likely that this 
rapid increase was missed in the in vitro 
analysis; however, similar increases in 
histone acetylation between 24 and 48 h 
were observed for both in vivo and in vitro 
acetylation. Western blotting of in vivo 
acetylation in one patient, representative 
of the other patients, displayed very weak 
acetylated histone H3 and stronger histone 
H4 acetylation (Fig. 7). The β-actin band 
intensity was also significantly lower than 
in the in vitro treated leukocytes, although 
total protein loadings were comparable. 
Although the relative differences in histone 
H3 and histone H4 are readily detectable, 
the quantitative differences in acetylation 
throughout the time course are not as clear. 
In our hands, flow cytometry appears to be 
a superior method for monitoring histone 
acetylation in vivo.
Discussion
In this report we have described three methods for detecting 
acetylated histones in blood mononuclear cells, and compared 
two common blood processing methods for their impact on his-
tone acetylation. For all methods, we have optimized the condi-
tions required for detecting histone acetylation, so that they can 
be readily adopted by other laboratories. We have also shown 
results from patients treated in vivo with LBH589 indicat-
ing that these methods also work effectively on clinical blood 
samples. While the HDACi we have based our methods on is 
LBH589, we anticipate that the methods we describe will be 
widely applicable for the monitoring of histone acetylation in 
the blood in the setting of any HDACi treatment, and are also 
sufficiently sensitive to detect histone acetylation in non-exposed 
cells. It should be noted, however, that while these methods are 
useful for assessing how the blood cells of an individual patient 
are responding to HDACi they do not necessarily correlate with 
how their tumor may be responding, nor with the clinical out-
come for an individual patient.
Our results suggest that leukocytes can be isolated from 
whole blood using either red blood cell lysis or density gradi-
ent separation with Ficoll-Paque, with little difference between 
the quantitative detection of histone H3 or H4 acetylation. For 
monitoring pediatric patients during treatment with HDACi, we 
suggest that processing blood by the red cell lysis method be the 
method of choice as there is no separation of the components 
of the leukocyte cell population (granulocytes, monocytes and 
lymphocytes) enabling smaller blood volumes to be processed. 
Some loss of histone acetylation was associated with blood pro-
cessing and this appeared equivalent between the two methods. 
Whether this is an active process of histone deacetylases or a 
non-specific “decay” has not as yet been determined.
cells are fixed immediately post LBH589 treatment, that they be 
analyzed within a week of fixing, to ensure the optimal retention 
of acetylated histones. Furthermore, these results suggest that 
consistent sample storage conditions should be maintained both 
after blood sample collection, and after sample fixing prior to the 
analysis of histone acetylation, to ensure the reliable measure-
ment of histone acetylation during a treatment time course, and 
to account for variations in histone acetylation that may occur in 
blood samples, post-collection.
Blood samples from four patients infused with LBH589 
were then analyzed to examine the general applicability of these 
methods to the measurement of histone acetylation during 
a treatment time course. The methods used were in the same 
way as described for the cord and peripheral blood samples. 
Six milliliters of peripheral blood was collected into EDTA 
tubes pre-treatment, 6, 24 and 48 h post a single 30 min 
infusion of 15 mg/m2 LBH589 that we estimated as equiva-
lent to a 1 μM in vitro dose. After collection, blood samples 
were transported to the laboratory at temperatures from 
4°C–16°C within 24 h, after which leukocytes were immedi-
ately separated from the blood by red cell lysis, and fixed for 
flow cytometry or stored as frozen pellets for western blotting. 
Flow cytometry was performed between 8 and 11 d after fix-
ing the cells, compared with 7 d in the in vitro study. Western 
blotting was performed after cell pellets had been stored for 
13 weeks at -80°C, compared with a storage time of 9 weeks 
for the in vitro analyses. Flow cytometry data showing the aver-
age in vivo levels of histone acetylation in the blood from four 
patients is shown in Figure 6. This data had similar fluorescence 
intensity values to the in vitro data in Figure 5, with histone H4 
acetylation higher than histone H3. However what is striking 
about the in vivo data are the kinetics of the histone acetylation 
with a rapid increase in the first 6 h after infusion followed by 
Figure 4. Immunohistochemistry. histone acetylation in leukocytes was detected with rabbit 
anti-acetylated histone h3 and histone h4 antibodies with anti-rabbit Alexa Fluor 488 as the sec-
ondary antibody. cells were counterstained with the nuclear DNA intercalating dye, DApI. The 
upper panel of cells shows the merge of the green Alexa Fluor 488 acetylated histone staining 
with the blue nuclear DApI stain, and the lower panels, acetylated histone staining alone. his-
tone h3 acetylation is less intense and localized to the periphery of the nucleus whereas histone 
h4 acetylation is more intense and concentrated within the nucleus.
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added to preparation media to prevent deacetylation of samples 
for ChIP.17 To preserve histone acetylation we recommend that 
blood samples are kept at 4°C for no longer than 48 h until 
leukocyte separation and analysis of histone acetylation by any 
method, that separated cell samples are kept on ice and cell pel-
lets frozen at -80°C as soon as practicable, and that cells for the 
analysis of histone acetylation by flow cytometry are fixed, but 
not stored for more than a week before being analyzed.
Visualization of histone acetylation in cord blood leuko-
cytes by immunohistochemistry showed cytoplasmic histone 
H4 acetylation in some instances consistent with the acetyla-
tion of mitochondrial histones previously described (results not 
shown).18 The majority of histone H3 and H4 acetylation was 
nuclear. Although immunohistochemistry is not quantitative, it 
can yield qualitative data on histone acetylation. The nuclear 
acetylation was spatially different for H3 and H4 with the H3 
acetylation appearing to be around the inside of the nuclear 
membrane and weakly dispersed through the nucleus whereas 
histone H4 staining was concentrated within the nucleus.
In their review, Kohler and Hurt19 indicated that chromatin 
is anchored, in both transcriptionally silent and active genes, to 
the nuclear pore complexes of the nuclear envelope with chro-
matin looping to the interior. They also noted that chromo-
some territories extend from the periphery to the interior of the 
nucleus20-22 with the regions of greater gene density located in 
the interior. Hyperacetylation of histone H4 lysine 5, lysine 12 
Significantly, the analysis of histone acetylation by flow 
cytometry under a range of post-treatment incubation tempera-
tures revealed differences in the levels of both histone H3 and 
H4 acetylation. The reduction in histone acetylation that pre-
dominantly affected leukocytes incubated at 37°C post LBH589 
treatment for 96 h, may be explainable by loss of histone acetyl 
transferase (HAT) activity due to thermal instability, as previ-
ously reported.11 The increased histone H3 acetylation observed 
at 48 and 72 h at 4°C and 20°C maybe due to effects of post-
treatment acetylation occurring in the absence of the addition of 
more inhibitor, an effect previously documented for LBH589 in 
clinical trials on lymphoma where prolonged effects were noted 
after the cessation of treatment.12 These effects are likely to be 
impacted by the relatively long half-life of LBH589 13 approxi-
mately 14 h (range 6.5–17.2) as compared with the comparatively 
shorter half-lives of other HDAC inhibitors.14-16 The counterbal-
ancing influences of loss of HAT activity and prolonged HDAC 
inhibition, may thus contribute to the increased variability in 
measurement of both histone H3 and H4 acetylation at later 
analysis time points.
It was also noted that although histone H3 and H4 acety-
lation was readily detectable in leukocytes for up to 96 h at 
4°C, 20°C or 37°C, fixed cells could not be stored long-term at 
4°C without significant losses in histone acetylation occurring. 
Deacetylation of fixed samples subsequently analyzed by flow 
cytometry has been noted previously10 and HDACi have been 
Figure 5. Analysis of histone acetylation by flow cytometry. Mean fluorescence values obtained from triplicate data sets of both median and mean 
fluorescence calculations for acetylated histone h3 or histone h4, obtained from flow cytometry. standard error of the statistical mean is indicated by 
the error bars. The y-axis shows the relative fluorescence intensity. DMsO diluent data were histogram subtracted from that of cells incubated with 100 
nM LBh589 and stored for the designated times. cells were fixed post-separation of the buffy coat (pre-treatment), 24 h after DMsO or LBh589 incuba-
tion (0 time), and thereafter at 24, 48, 72 and 96 h storage at 4°c, 20°c or 37°c. The fixed cells were stained for histone h3 and histone h4 acetylation 
and analyzed by flow cytometry. six hundred and ninety-seven cells incubated with LBh589 for 24 h were included as controls. White bars represent 
histone acetylation data after incubation at 4°c, gray bars 20°c and black bars 37°c.
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HREC 30025A). Peripheral blood from four 
patients enrolled on a Phase I study to exam-
ine the therapeutic effectiveness of LBH589 
in pediatric patients with refractory solid 
tumors (CLBH589AAU03T) was included in 
the study to ascertain concordance between 
in vitro and in vivo data.
LBH589. LBH589 (NVP-LBH589 CU-4) 
was provided by Novartis. LBH589 for intra 
venous use is supplied as a sterile, single use 
vial of 25 mg/5 ml solution containing lactic 
acid, mannitol and propylene glycol. For in 
vitro studies, a 25 mM stock solution was pre-
pared in cell culture tested DMSO (Sigma) 
from which a 10 μM working stock in DMSO 
was prepared. Stocks were stored at -20°C.
Viable cell counts. Equal volumes of cell 
suspensions and trypan blue (Sigma) were 
mixed and loaded onto a hemocytometer. 
Cells excluding trypan blue were deemed 
viable.
Separation of leukocytes. Ficoll-Paque 
PLUS separation of mononuclear cells. An equal 
volume of PBS was added to 2 mL blood, 
mixed and overlaid onto 3 mL of Ficoll-Paque 
PLUS (GE Life Sciences). Following centrifu-
gation for 30 min at 400 g without a break, 
the interface leukocyte layer was collected 
and transferred to a 15 mL tube containing 
6 mL of PBS. The tubes were gently inverted 
then centrifuged at 350 g for 5 min, the cells 
resuspended in PBS and counted using a 
hemocytometer.
Red cell lysis. Ten volumes of sterile ice-cold red cell lysis buf-
fer (155 mM NH
4
Cl, 10 mM KHCO
3
, 1 mM Na
2
EDTA, pH 
7.2–7.4) were added to one volume of fresh whole cord blood, 
inverted and incubated on ice for 5–10 min until the solution 
became translucent, with intermittent mixing. The tubes were 
centrifuged at 350 g for 10 min at 4°C, the supernatant aspi-
rated and the leukocyte pellet resuspended in 5 volumes of red 
cell lysis buffer. The sample was again centrifuged at 350 g for 5 
min at 4°C, and the supernatant aspirated completely to leave a 
clean white cell pellet. Red cell contamination results in hemo-
globin auto-fluorescence and interferes with histone detection in 
the fluorescent western blotting system. Cells were resuspended 
in PBS and counted using a hemocytometer. Peripheral blood 
erythrocytes have greater osmotic fragility than cord blood, and 
a 3:1 ratio of buffer to blood was used when processing peripheral 
blood.
HDACi treatment. A amount of 1 × 107 leukocytes per well 
in was suspended in 2 mL of RPMI cell culture medium con-
taining 10% fetal bovine serum (FBS) in a 6 well plate (Costar). 
Sample wells contained 100 nM LBH589 (Novartis) or 0.1% 
DMSO. The cells were incubated for 24 h at 37°C with 5% 
CO
2
 in air. Cells were then washed and processed according 
to the test required. For re-separation from blood, cells were 
Figure 6. Analysis of in vivo leukocyte histone acetylation by flow cytometry. Mean and me-
dian fluorescence values for histone h3 and histone h4 acetylation in four sets of leukocytes 
over a treatment course, obtained by flow cytometry. The standard error of the statistical 
mean is indicated by the error bars. The y-axis shows the relative fluorescence intensity. 
pre-treatment patient data were histogram subtracted from that of cells collected 6, 24 and 
48 h post a single 30 min infusion of 15 mg/m2 LBh589. cells were fixed post-separation from 
blood by red cell lysis. The fixed cells were stained for histone h3 and histone h4 acetylation 
and analyzed by flow cytometry.
and, less so, lysine 16, is associated with transcription and chro-
mosome movement.23 Histone H4 hyperacetylation has been 
suggested24 to cause a conformational change to the nucleosome 
that exposes the DNA to allow the binding of transcription fac-
tors, the most highly acetylated H4 being the most attractive to 
transcription factors.25 Histone H3 acetylation has been shown 
to be important for the assembly of chromatin and for transcrip-
tion,24 with histone H3 monomethylated at K4 with K9/K14 
acetylated as markers of active gene expression.26 It would be 
interesting to build upon these results using individual antibod-
ies for each acetylated lysine site. The qualitative visualization 
of the acetylation of histone H3 and H4 can give some insights 
into to the biological activity that may be occurring that are not 
apparent from flow cytometry and western blotting alone.
Materials and Methods
In this study we tested both umbilical cord and peripheral blood 
in vitro to monitor how processing and environmental condi-
tions impact histone acetylation. Umbilical cord blood samples 
deemed unsuitable for transplantation were available from the 
institutional cord blood bank and ethics approval was granted 
for their use in this study (Ethics approval #HREC 29092A and 
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Sciences). The density of the bands detected by the Cy3 (β actin) 
and Cy5 (acetyl histone) antibodies were quantified on separate 
color channels and the data exported to Excel (Microsoft). Data 
for the acetyl-histones were adjusted for concentration relative to 
the Beta actin bands. The band density of the lysates from cells 
exposed to the control diluent DMSO was subtracted from that 
of cells exposed to LBH589. Data were then normalized to the 
control 697 cell sample.
Flow cytometry. Flow cytometry was based on the method of 
Ronzoni et al. 2005. Briefly, 8 × 105 leukocytes were resuspended 
in PBS containing 1% FBS, centrifuged and resuspended in 
200 μL 1% paraformaldehyde. The cells were incubated on ice for 
15 min, washed in 2 mL ice-cold PBS, resuspended in 200 μL of 
PBS, and stored at 4°C for a maximum of one week. Immediately 
prior to use, the cells were washed with PBS containing 1% BSA 
and permeabilized with 200 μL of 0.1% Triton X-100 in PBS 
for 10 min at room temperature. After washing with PBS/1% 
BSA, the samples were blocked in 500 μL of PBS/10% FBS for 
20 min. Histone acetylation levels were detected by incubation 
with polyclonal rabbit anti-acetyl histone H3 or rabbit anti-acetyl 
histone H4 antibodies for 1 h and then washed and incubated 
with donkey anti-rabbit IgG AF488 for 1 h at room temperature 
in the dark. Cells were washed and resuspended in 200 μL PBS, 
and stored at 4°C overnight in the dark until analyzed.
Flow cytometry analysis. Flow cytometry was performed on 
a LSR II flow cytometer (Becton Dickinson), acquiring 10,000 
events/sample. The instrument was equipped with a band-pass 
530/30-nm optical filter for AF488 fluorescence detection with 
488 nm excitation wavelength, and a 440/40-nm optical filter 
in the DAPI channel detector. Data were collected using the BD 
FACSDiva software, and further analyzed using the software 
package FCS express. DMSO diluent data at each time point was 
histogram subtracted, channel by channel, from fluorescence data 
obtained from 100 nM LBH589 treatment of peripheral blood 
leukocytes. After control histogram subtraction, the mean and 
median fluorescence for each treatment time point was derived.
resuspended in 1 mL PBS/1% FBS and added to 1 mL of leu-
kocyte depleted blood. The leukocytes were removed by repeated 
centrifugation and aspiration of the buffy coat. The 697 leuke-
mia cell line (ATCC) was grown in RPMI containing 10% FBS. 
107 cells per mL were incubated in 100 nM LBH589 for 24 h at 
37°C with 5% CO
2
. The cells were washed in PBS and processed 
for western blotting, flow cytometry or immunohistochemistry 
where they were used as acetylation controls.
Blood histone acetylation data from four patients are reported 
in this study. Patients were aged 9–14 y and were subjected to a 
single 30 min infusion of 15 mg/m2 of LBH589. Pre-treatment, 6, 
24 and 48 h post treatment bloods were collected in EDTA tubes 
in accordance with the trial protocol and stored at 4°C for up to 
24 h before processing.
Antibodies. For western blotting, flow cytometry and immu-
nohistochemistry antibodies were used at the following indi-
cated concentrations: Primary antibodies rabbit anti-Acetyl 
Histone H3 K9/K14 Millipore #06-599 (1:1500, 1:500, 1:200) 
rabbit anti-Acetyl Histone H4 Millipore Cat #06-598 (1:1500, 
1:500, 1:200) and mouse anti-β actin Sigma #A5316 (1:5,000). 
Secondary antibodies: Goat anti-rabbit Cy5 GE Life Sciences 
#PA45012 and Goat anti-mouse Cy3 GE Life Sciences #PA43010 
(both 1:3000) for western blotting and donkey anti-rabbit IgG 
(H + L) Alexa Fluor 488 (Invitrogen #A21206) for flow cytom-
etry (1:1000) and immunohistochemistry (1:500).
Western blotting. An amount of 1 × 107 leukocytes (incu-
bated with LBH589 or DMSO) was washed in ice-cold sterile 
PBS, centrifuged at 2,000 g for 10 min at 4°C, the supernatant 
aspirated and the cells frozen at -80°C. The cell pellet was thawed 
on ice prior to the addition of 200 μL ice-cold mammalian lysis 
buffer [50 mM Tris pH 7.5, 375 mM sodium chloride, 1 mM 
disodium EDTA, 1% Triton X-100, protease inhibitor cocktail 
(Merck #539131)] and the sample sonicated for 1 min. Samples 
were maintained on ice. An amount of 5× loading buffer (0.25 
M Tris pH 6.8, 0.2% bromophenol blue, 10% sodium dodecyl 
sulfate, 50% Glycerol, 10% β mercaptoethanol) was added to 20 
μg of the lysed sample, denatured at 96°C for 10 min, and then 
run on15% SDS-PAGE gels at 100 V. Hybond-LFP membrane 
(GE Life Sciences) was prepared according to the manufacturer’s 
instruction and protein transfer conducted at 40 V (maximum 
400 mA) at 4°C for 2 to 2.5 h. The transferred membrane was 
rinsed briefly in methanol, PBS and then blocked in 5% non-fat 
dry milk (Fonterra) in PBS for 1 h at room temperature. The mem-
brane was rinsed three times in phosphate buffered saline/0.1% 
Tween 20 (PBST) and incubated 4°C overnight in the combined 
primary antibodies (rabbit anti-acetyl histone H3, rabbit anti-ace-
tyl histone H4 and mouse anti-β-actin) in PBST. The membrane 
was washed twice for 5 min in PBST prior to incubation with the 
secondary antibodies (Goat anti-rabbit Cy5 and Goat anti-mouse 
Cy3) for 1 h at room temperature. Following antibody incuba-
tions, the membrane was rinsed in PBST and PBS before being 
read in the Typhoon Trio Variable Mode Imager Membranes were 
scanned on fluorescence, 100 micron setting, using Cy3 Emission 
filter 580BP30 and Cy5 Emission filter 670BP30.
Western blot analysis. Scanned membranes from west-
ern blots were analyzed using ImageQuant software (GE Life 
Figure 7. Western blot showing histone h3 and h4 acetylation in vivo 
in leukocytes from a single patient. Twenty micrograms of protein was 
loaded in each lane of a 15% sDs-pAGE gel. Rabbit anti-acetyl histone 
h3 detected a protein band at approximately 16 KDa and rabbit anti-
acetyl histone h4 detected a band at 12 KDa; mouse anti-β-actin (the 
loading control) recognized a protein band at 42 KDa. The secondary 
antibody anti-mouse cy3 has red fluorescence and the anti-rabbit cy5 
has green fluorescence. Lane 1, size marker. Lane 2, pre-treatment leu-
kocytes. Lane 3, 6 h post treatment. Lane 4, 24 h post treatment. Lane 
5, 48 h post treatment. Lane 6, control 697 cells incubated with 100 nM 
LBh589 for 24 h.
© 2012 Landes Bioscience.
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Slides were stored overnight at room temperature in the dark 
until read.
Confocal microscopy. Slides were read and digital imaging 
was performed using a Leica DM IRE2 Confocal microscope, 
with an HCX PL APO CS 63 × 13 mm IMM objective with 
glycerol immersion media and Leica Confocal Software. High 
power images were at 3–3.5× optical zoom, voxel size 80–90. 
LAS AF lite software was used to overlay the separate Alexa 
Fluor488 and DAPI images.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
This work was supported by a grant from Novartis (L.R.) and 
by funding from the Children’s Cancer Centre Foundation 
(E.A.) and the Steven Walter Foundation (A.M.). The MCRI 
is supported by the Victorian Government’s Operational 
Infrastructure Support Program. We thank Matt Burton for 
assistance with flow cytometry.
Immunohistochemistry. Leukocytes were resuspended at 
5 × 105/mL in cold PBS/0.1% FBS on ice and 200 μL of cells 
were spun onto clean microscope slides in a SHANDON 
2 Cytospin centrifuge at 500 rpm for 3 min. Slides were air-
dried for 30 min, encircled with hydrophic “ink” (mini PAP 
pen Invitrogen #00-887) then fixed in 80 μL 1% paraformal-
dehyde in PBS for 5 min, washed twice in PBS and air-dried 
prior to storage at 4°C. Slides were warmed to room temperature 
before staining, permeabilized in 80 μL 0.1% Triton X-100 in 
PBS for 3 min, washed once in PBS for 15 min, then in PBST 
and blocked in 100 μL of 5% BSA (or serum of second anti-
body) in PBS for 60 min. Slides were washed twice for 5 min 
in PBST and then incubated in 50 μL α-acH3 or α-acH4 anti-
body in 1% BSA containing 0.3% Triton X-100 in PBST for 120 
min at ambient temperature or overnight at 4°C in a humidi-
fied container. Slides were washed three times for 5 min with 
PBST prior to incubation in 50 μL anti-rabbit AF488 (1:500) 
in 1% BSA in PBST for 60 min at ambient temperature. Slides 
were washed in PBST then mounted in ProLong® Gold + DAPI 
(#P36935 Invitrogen) and left to cure for 24 h in the dark. 
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